Literature DB >> 2664372

An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer.

H O Klein1, J Wils, H Bleiberg, M Buyse, N Duez.   

Abstract

Until now advanced gastric cancer has been generally treated with the FAM chemotherapy protocol. Due to the relatively low response rates with this protocol we decided to start a randomized prospective phase II trial comparing the FAM with the FAMTX protocol. The primary aim of our trial was to compare the toxicity in both protocols. The FAMTX protocol has been demonstrated to be fully comparable with the toxicity of the FAM protocol. The trial has been extended to a phase III study. With respect to response rates and survival times it is too early for evaluation.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2664372     DOI： 10.1007/bf02985241

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN： 0736-0118


  8 in total

1.  A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.

Authors:  S A Cullinan; C G Moertel; T R Fleming; J R Rubin; J E Krook; L K Everson; H E Windschitl; D I Twito; R F Marschke; J F Foley
Journal:  JAMA       Date:  1985-04-12       Impact factor: 56.272

2.  Chemotherapy in advanced gastric cancer.

Authors:  D Cunningham; N L Gilchrist; G J Forrest; M Soukop; C S McArdle; D C Carter
Journal:  Cancer Treat Rep       Date:  1985 Jul-Aug

3.  An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer.

Authors:  J Wils; H Bleiberg; O Dalesio; G Blijham; N Mulder; A Planting; T Splinter; N Duez
Journal:  J Clin Oncol       Date:  1986-12       Impact factor: 44.544

4.  Analysis of survival by tumor response.

Authors:  J R Anderson; K C Cain; R D Gelber
Journal:  J Clin Oncol       Date:  1983-11       Impact factor: 44.544

5.  An EORTC Gastrointestinal Group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and adriamycin in advanced gastric cancer.

Authors:  A Lacave; J Wils; H Bleiberg; E Diaz-Rubio; N Duez; O Dalesio
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

6.  Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC).

Authors:  V De Lisi; G Cocconi; M Tonato; F Di Costanzo; F Leonardi; M Soldani
Journal:  Cancer Treat Rep       Date:  1986-04

7.  [Chemotherapy schedule for the management of metastasizing gastric cancer. Methotrexate, adriamycin and 5-fluorouracil].

Authors:  H O Klein; P D Wickramanayake; F Dieterle; R Mohr; H Oerkermann; J Brock; D Beyer; R Gross
Journal:  Dtsch Med Wochenschr       Date:  1982-11-12       Impact factor: 0.628

8.  5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.

Authors:  J S MacDonald; P S Schein; P V Woolley; T Smythe; W Ueno; D Hoth; F Smith; M Boiron; C Gisselbrecht; R Brunet; C Lagarde
Journal:  Ann Intern Med       Date:  1980-10       Impact factor: 25.391
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.